![]() |
|
|






* Nutritional Science Research Group, Division of Cancer Prevention, National Cancer Institute, National Institutes of Health, Department of Health and Human Services, Bethesda, MD 20892;
Vascular Biology Research Program, Division of Heart and Vascular Diseases, National Heart, Lung, and Blood Institute, National Institutes of Health, Department of Health and Human Services, Bethesda, MD 20892;
** Department of Nutrition, University of California-Davis, Davis, CA 95616;
Ohio State University, College of Engineering, Biomedical Engineering Center, Ohio State University, Columbus, OH 43210;

Department of Environmental Health Sciences, University of Michigan, Ann Arbor, MI 48109; and

Chemical Sciences Division, Oak Ridge National Laboratory, Oak Ridge, TN 37831
2To whom correspondence should be addressed. E-mail: rosssha{at}mail.nih.gov.
| ABSTRACT |
|---|
|
|
|---|
KEY WORDS: bioactive food components food science accelerator mass spectrometry nanotechnology proteomics
New and emerging technologies such as microarray technology and nanotechnology have the potential to advance the science of nutrition by assisting in the discovery, development, and delivery of several intervention strategies to improve health and to reduce the risk and complications of several diseases. Some of the areas that would benefit most from emerging technologies include identifying sites of action (molecular targets) for bioactive food components (including essential and nonessential bioactive food components); characterizing biomarkers that reflect exposure, response, and susceptibility to foods and their components; and perhaps the identification of new target delivery systems for optimizing health.
Microarray technology, for example, is a powerful tool that is increasingly being employed in nutrition research (1), and additional biological insights employing this methodology are certain to surface. Genome-wide monitoring of gene expression is now possible using DNA microarrays, which allow the simultaneous assessment of the transcription of tens of thousands of genes and of their relative expression between normal cells and pathological cells such as tumor cells. Microarray analysis of gene expression profiles is likely to be useful in identifying critical sites of action and in pinpointing molecular targets as potential biomarkers. For example, microarray analysis of gene expression profiles can be used to identify the similarities and differences between bioactive food components and to identify critical sites of action of the component in specific tissues (2). More recently, microarray technology has been used to probe protein expression or epigenetic events such as DNA methylation and histone acetylation (3,4). Such revolutionary technologies may lead to the discovery of new biomarkers for early disease detection and prognosis prediction, and of new tools for prevention and therapy of diseases.
"Nanotechnology" is defined as the creation of functional materials, devices, and systems through control of matter at the scale of 1 to 100 nm, and the exploitation of novel properties and phenomena at the same scale (5) (nano, derived from Greek, means dwarf). Such technology offers the possibility of examining biological processes when limited by sampling issues. This emerging field is likely to be critical for enabling breakthroughs of new and effective tools in the medical sciences (i.e., nanomedicine) (6). Medical uses for nanotechnology include development of nanoparticles for diagnostic and screening purposes (i.e., early detection of cancer), development of artificial receptors, DNA sequencing using nanopores, manufacture of unique drug (and perhaps nutrient) delivery systems, as well as gene therapy and tissue engineering applications (6,7). Nanomachines able to circulate through the bloodstream, kill microbes, or undo tissue damage could be delivered to the human body through medicines or even foods. Significant progress in the development of sensors for rapid detection of pathogens in foods or the environment has been made in part due to discoveries and tools of nanotechnology. For example, a real-time PCR-detection approach provided significant advancements to PCR-based methods for the rapid detection of food pathogens (8). Nanotechnology applications in nutrition research may assist with obtaining accurate spatial information of a nutrient or bioactive food component in tissue and low-level detection of essential and nonessential nutrients and metabolites, as well as increasing an understanding of nutrient and biomolecular interactions in specific tissues. In theory, new technologies have the potential to improve nutritional assessment and measures of bioavailability and may help to identify and characterize molecular targets of nutrient activity and biomarkers of effect, exposure, and susceptibility.
To highlight emerging technologies and to encourage collaboration between various disciplines, with the aim of advancing nutritional sciences, a symposium was convened at Experimental Biology 2003 on the topic "New Technologies for Nutrition Research." This session presented a cross-section of exciting and emerging technological approaches for the study of nutrition and chronic disease prevention. Experts focused on topics that included "Nanotechnology in vivo: an emerging paradigm" (presented by Stephen C. Lee, Ohio State University); "Nutrient metabolism at attomole levels: accelerator mass spectrometry for ultra-low level radiolabel tracing in nutrition" (presented by Andrew J. Clifford, University of California-Davis); "Nanotechnology: a tool for the food science and technology of the new millennium" (presented by Carmen I. Moraru, Rutgers, the State University of New Jersey); "Nanodevices for real-time optical intracellular sensing" (presented by Martin A. Philbert, University of Michigan); and "Mass spectrometric techniques for following gene and protein expression" (presented by Robert L. Hettich, Oak Ridge National Laboratory). The sections that follow provide a synopsis of each of the topics presented with highlights for nutrition research applications where possible.
| Nanotechnology in vivo: an emerging paradigm |
|---|
|
|
|---|
The more sophisticated interventions afforded by nanotherapeutics are likely to depend on a combination of therapeutic targeting to disease sites, controlled release of therapeutics preferentially at disease sites, and by differential device activity in different physiological environments, potentially under direction of an external physician/ operator. These attributes will maximize the benefit of therapy at disease sites while minimizing systemic toxicities (1315).
Many emerging nanotherapeutics are essentially delivery devices based on nanoparticulate materials (allowing minimally invasive parenteral administration), with a strong emphasis on control of therapeutic action in time and space. Targeted delivery devices depending on biologic affinity interactions [using the emerging vascular address system (16,17)] as well as others depending on physical/chemical properties of nanoscale particulates (enhanced permeability and retention effect, 1719) have emerged in recent years, as have pro-drug strategies for delivery devices that are active only at preselected sites of disease (17,1921). Other related modalities have allowed the control of activity or assembly of functional nanodevices at particular sites or at particular times in response to a signal provided by an external operator. Such signals might be physical [a magnetic field, 22)] or biochemical [an enzyme to process the therapeutic to an active form (23,24)] in nature.
Emerging in vivo nanotechnology will allow clinicians unprecedented abilities to monitor therapy in real time, as well as stringent control of the systemic consequences of therapy. These benefits of nanotherapeutics are likely to be pursued first for disease states exhibiting large unmet patient needs (oncology, cardiovascular disease). In time, lessons learned from specific delivery of potentially toxic materials to maximize their therapeutic benefits might be applied to other in vivo delivery tasks, such as delivery and distribution of nutrients and nutraceuticals.
| Nutrient metabolism at attomole levels: accelerator mass spectrometry for ultra-low level radiolabel tracing in nutrition |
|---|
|
|
|---|
7-d duration of previous studies (bar one) of folate metabolism is too short to resolve body folate pools that turn over most slowly. The slow turning over pools can be a major determinant of plasma folate kinetics late in a study. Dr. Clifford described an experimental approach for using accelerator mass spectrometry (AMS) and kinetic modeling of the resulting data to quantify the dynamic and kinetic behavior of human folate metabolism under normal conditions and how it might respond to single nucleotide polymorphisms in their folate relevant genes. In the research described, a very low dose of 14C-labeled pteroylmonoglutamate (0.5 nmol, 100 nCi) plus 79.5 nmol pteroylmonoglutamate was ingested by each of 13 normal adults. Complete collections of urine and feces were made for at least 28 and 14 d, respectively. Up to 47 serial blood samples were collected in the 150 d that followed dosing. The 14C in all specimens was analyzed (27,28) and the dataset was analyzed by organizing current concepts of folate metabolism into a model suitable for quantitative hypothesis testing (29,30).
The study revealed the following: 1) absorbed dose is 79% of the dose administered; 2) mean dietary folate intake is 1046 nmol/d, bile folate is 5351 nmo/d, and 92% of the mix (1046 + 5351) is absorbed; 3) 1/4 of 1% of plasma folate is destined for RBC production; 4) about 35% of folate taken up by viscera is processed to polyGlu forms; 5) plasma residence time is on the order of 10 min; 6) nearly all body folate is visceral and nearly all visceral folate is PolyGlu; 7) folate uptake by marrow is saturable at about 1 mmol/d; 8) visceral PolyGlu is a direct precursor of p-ABA-Glu; and 9) preliminary data suggests that single nucleotide polymorphisms in folate relevant genes are likely to alter some of the above listed aspects of human folate metabolism. Finally, it is important to note that parameters, such as mean residence times, distributions, and fluxes, etc., of folate are explicitly model-dependent. Future experiments may require model revision; then these derived features of folate metabolism may require revision also. At the same time, and because AMS can detect attomole levels of 14C, ultra low-level doses (
130 kBq of 14C that impart a lifetime added radiation exposure equivalent to that from a 15-min-flight at jetliner altitude) will provide datasets for elucidating the metabolism of several nutrients and bioactive dietary components in order to better match needs to genetic make-up and physiologic status of individuals.
| Nanotechnology: a tool for the food science and technology of the new millennium |
|---|
|
|
|---|
A significant benefit for health and nutrition is poised to arise from more efficient delivery systems, able to deliver the active compounds directly to the appropriate sites, maintain their concentration at suitable levels for long periods of time, and prevent their premature degradation. Nanostructured materials, such as nanoparticles and nanospheres, could be used in the future to develop high performance delivery vehicles for biologically active substances of food origin, such as nutraceuticals (31). Another exciting development in this area is anticipated to be the use of nanostructured carriers for enhanced encapsulation and delivery of flavors in foods. Research efforts are already being made to develop food-based delivery vehicles such as polysaccharide/protein coacervates, liposomes or dendrimers. Stable phospholipid-divalent cation precipitates composed of naturally occurring materials, called cochleates, have been developed and patented (32). Cochleates are used for the encapsulation and delivery of a wide range of bioactive materials, including compounds with poor water solubility, protein and peptide drugs, large hydrophilic molecules, and in the future they could also be applied to the encapsulation and targeted delivery of functional food biomolecules.
In the food packaging arena, nanomaterials with enhanced mechanical and thermal properties are being developed to ensure better protection of foods from the exterior mechanical, thermal, chemical, or microbiological factors. Nanostructuring adds value to traditional materials by enhancing their mechanical strength, superconductivity, and ability to incorporate and efficiently deliver active substances into biological systems, at low costs and limited environmental impact. This would endow an additional level of safety and functionality to packaged foods. A promising class of new materials is represented by nanocomposites, made out of nanoscale structures with morphology and interfacial properties that give them unique characteristics. Nanocomposites started being used for coating plastic films as an alternative to silica and alumina coated films for food packaging. The addition of natural nanostructured materials (i.e., natural smectite clays) can render plastics that are lighter, stronger, and more heat-resistant, with improved oxygen, carbon dioxide, moisture, and volatile barrier properties (31,33). Such materials could enhance considerably the shelf life and safety of packaged foods.
Many of the microbial safety problems encountered in the food industry are related to the contamination of food processing equipment and surfaces with bacteria and bacterial and fungal spores. One of the most important properties of microbial cells and spores related to surfaces contamination and biofouling is adhesion. The quantification of microbial adhesion has been facilitated by the development of nanotools such as the Atomic Force Microscope (AFM) (31,34). Nanotechnology based strategies involving modification of surface chemistry and structure will probably be used in the future to prevent bacteria from adhering to food processing equipment.
A variation of this technology could involve the active coating of food contact surfaces for controlled release of antimicrobial compounds, triggered by environmental conditions such as temperature and humidity. In the same area of food safety, newly developed antimicrobial nanoemulsions are finding applications in decontamination of food equipment, packaging, or even the surface of some foods (i.e., fruits and vegetables). Additionally, nanotechnology is helping design antigen detecting biosensors to facilitate the early identification of pathogen contamination, thereby increasing the security of the food supply.
Another topic that was discussed was biomaterial characterization at the nanoscopic level. AFM is currently used to study the topography of foods and other biomaterials, and also for the structural investigation of delicate food biopolymer structures, such as hylan, xanthan gum, or kappa-carageenan gels. Force microscopy techniques enabled the study of rheological properties of single chains of proteins, polysaccharides, or DNA, and the intra- and intermolecular interactions in which these molecules participate (31,35,36). AFM force measurements allow quantifying the nano-mechanical properties of biofilm surfaces, which has many potential applications for foods and other biological soft materials.
Overall, nanotechnology offers a myriad of new and exciting opportunities for better understanding the structure and functionality of food systems, which is expected to result in improved nutritional quality and safety of foods, to the benefit of the science, industry, but first of all of the consumers.
| Nanodevices for real-time optical intracellular sensing |
|---|
|
|
|---|
| Mass spectrometric techniques for following gene and protein expression |
|---|
|
|
|---|
| Concluding Remarks |
|---|
|
|
|---|
| ACKNOWLEDGMENTS |
|---|
| FOOTNOTES |
|---|
3 Abbreviations used: AFM, Atomic Force Microscope; AMS, accelerator mass spectrometry; ESI, electrospray ionization; LC-MS/MS, liquid chromatography tandem mass spectrometry; MALDI, matrix assisted laser desorption/ionization; MS, Mass spectrometry; PEBBLE, probes encapsulated by biologically localized embedding; PolyGlu, pteroylpolyglutamate. ![]()
| LITERATURE CITED |
|---|
|
|
|---|
1. Page, G. P., Edwards, J. W., Barnes, S., Weindruch, R. & Allison, D. B. (2003) A design and statistical perspective on microarray gene expression studies in nutrition: the need for playful creativity and scientific hard-mindedness. Nutrition 19:997-1000.[Medline]
2. Muller, M. & Kersten, S. (2003) Nutrigenomics: goals and strategies. Nat. Rev. Genet. 4:315-322.[Medline]
3. Shi, H., Wei, S. H., Leu, Y. W., Rahmatpanah, F., Liu, J. C., Yan, P. S., Nephew, K. P. & Huang, T. H. (2003) Triple analysis of the cancer epigenome: an integrated microarray system for assessing gene expression, DNA methylation, and histone acetylation. Cancer Res. 63:2164-2171.
4. Chen, C. M., Chen, H. L., Hsiau, T. H., Hsiau, A. H., Shi, H., Brock, G. J., Wei, S. H., Caldwell, C. W., Yan, P. S. & Huang, T. H. (2003) Methylation target array for rapid analysis of CpG island hypermethylation in multiple tissue genomes. Am. J. Pathol. 163:37-45.
5. Srinivas, P. R., Barker, P. & Srivastava, S. (2002) Nanotechnology in early detection of cancer. Lab. Invest. 82:657-662.[Medline]
6. Emerich, D. F. & Thanos, C. G. (2003) Nanotechnology and medicine. Expert Opin. Biol. Ther. 3:655-663.[Medline]
7. Bogunia-Kubik, K. & Sugisaka, M. (2002) From molecular biology to nanotechnology and nanomedicine. Biosystems 65:123-138.[Medline]
8. Bhagwat, A. A. (2003) Simultaneous detection of Escherichia coli O157: H7, Listeria monocytogenes and Salmonella strains by real-time PCR. Int. J. Food Microbiol. 84:217-224.[Medline]
9. Lee, S. C. Savage, L. eds. Biological Molecules in Nanotechnology: the Convergence of Biotechnology, Polymer Chemistry and Materials Science 1998 IBC Press Southborough, MA. .
10. Lee, S. C. (1998) Biotechnology for nanotechnology. Trends Biotechnol. 16:239-240.
11. Lee, S. C. (2001) Dendrimers in nanobiological devices. Tomalia, D. Frechet, J. eds. Dendrimers and other Dendritic Polymers 2001:548-557 John Wiley & Co. London, England. .
12. Jelinski, L. (1999) Biologically related aspects of nanoparticles, nanostructural materials, and nanodevices. Siegel, R. W. Hu, E. Roco, M. C. eds. Nanostructure Science and Technology 1999:113-130 Kluwer Academic Publishers Dordrecht, The Netherlands. .
13. Goldin, D. S., Dahl, C. A., Olsen, K. L., Ostrach, L. H. & Klausner, R. D. (2001) The NASA-NCI Collaboration on Biomolecular Sensors. Science 292:443-444.
14. Lee, S. C., Reugsegger, M., Barnes, P. D., Smith, B. R. & Ferrari, M. (2004) Therapeutic nanodevices. Bhushan, B. eds. The Nanotechnology Handbook 2004:279-322 Springer-Verlag Heidelberg, Germany. .
15. Buxton, D. B., Lee, S. C., Wickline, S. A. & Ferrari, M. (2003) Recommendations of the National Heart, Lung, and Blood Institute Nanotechnology Working Group. Circulation 108:2737-2742.
16. Arap, W., Haedicke, W., Bernasconi, M., Kain, R., Rajotte, D., Krajewski, S., Ellerby, H. M., Bredesen, D. E., Pasqualini, R. & Ruoslahti, E. (2002) Targeting the prostate for destruction. through a vascular address. Proc. Natl. Acad. Sci. U.S.A. 99:1527-1531.
17. Baker, J. R., Jr, Quintana, A., Piehler, L., Banaszak-Holl, M., Tomalia, D. & Raczke, E. (2001) The synthesis and testing of anti-cancer therapeutic nanodevices. J. Biomed. Microdevices 3:61-69.
18. Quintana, A., Raczka, E., Piehler, L., Lee, I., Myc, A., Majoros, I., Patri, A. K., Thomas, T., Mule, J. & Baker, J. R., Jr (2002) Design and function of a dendrimer-based therapeutic nanodevice targeted to tumor cells through the folate receptor. Pharm. Res. 19:1310-1316.[Medline]
19. Duncan, R. (1997) Polymer therapeutics for tumor specific delivery. Chemistry and Industry 7:262-264.
20. Duncan, R., Gac-Breton, S., Keane, R., Musila, R., Sat, Y. N., Satchi, R. & Searle, F. (2001) Polymer-drug conjugates, PDEPT and PELT: Basic principles for design and transfer from the laboratory to the clinic. J. Cont. Release 74:135-146.
21. Maeda, H., Sawa, T. & Konno, T. (2001) Mechanism of tumor-targeted delivery of macromolecular drugs, including the EPR effect in solid tumor and clinical overview of the prototype polymeric drug SMANCS. J. Cont. Release 74:47-61.
22. Hamad-Schifferli, K., Schwartz, J. J., Santos, A. T., Zhang, S. & Jacobson, J. M. (2002) Remote electronic control of DNA hybridization through inductive coupling to an attached metal nanocrystal antenna. Nature 415:152-155.[Medline]
23. Meers, P. (2001) Enzyme-activated targeting of liposomes. Adv. Drug Deliv. Rev. 53:265-272.[Medline]
24. Ma, Z. & Taylor, J.-S.. (2000) Nucleic acid-triggered catalytic drug release. Proc. Natl. Acad. Sci. U.S.A. 97:11159-11163.
25. Clifford, A. J., Arjomand, A., Dueker, S. R., Schneider, P. D., Buchholz, B. A. & Vogel, J. S. (1998) The dynamics of folic acid metabolism in an adult given a small tracer dose of 14C-folic acid. Adv. Exp. Med. Biol. 445:239-251.[Medline]
26. Lin, Y., Dueker, S. R., Follett, J. R., Fadel, J. G., Schneider, P. D., Miller, J. W., Green, R., Buchholz, B. A., Vogel, J. S., Phair, R. D. & Clifford, A. J. (2004) Quantitation of in vivo human folate metabolism. Am. J. Clin. Nutr. (in press).
27. Vogel, J. S., Turteltaub, K. W., Finkel, R. & Nelson, D. E. (1995) Accelerator mass spectrometry: isotope quantification at attomole sensitivity. Anal. Chem. 67:A353-A359.[Medline]
28. Vogel, J. S., Dueker, S. R., Lin, Y., Clifford, A. J., Ognibene, T., Hillegonds, D. & Buchholz, B. A. (2004) Quantifying human vitamin kinetics with AMS. Synthesis and application of isotopically labeled compounds 2004 Wiley and Sons Chichester, UK (in press).
29. Phair, R. D. (1997) Development of kinetic models in the nonlinear world of molecular cell biology. Metabolism 46:1489-1495.[Medline]
30. Phair, R. D. & Misteli, T. (2001) Kinetic modeling approaches to in vivo imaging. Nat. Rev. Mol. Cell Biol. 2:898-907.[Medline]
31. Moraru, C. I., Panchapakesan, C. P., Huang, Q., Takhistov, P., Liu, S. & Kokini, J. L. (2003) Nanotechnologya new frontier in Food Science. Food Technol. 57:24-29.
32. Gould-Fogerite, S., Mannino, R. J. & Margolis, D. (2003) Cochleate delivery vehicles: Applications to gene therapy. Drug Delivery Technol. 3:40-47.
33. Moore, S. (1999) Nanocomposite achieves exceptional barrier in films. Modern Plastics 76:31-32.
34. Razatos, A., Ong, Y., Sharma, M. M. & Georgiou, G. (1998) Molecular determinants of bacterial adhesion analyzed by atomic force microscopy. Proc. Natl. Acad. Sci. U.S.A. 95:11059-11064.
35. McIntire, T. M. & Brant, D. A. (1997) Imaging of individual biopolymers and supramolecular assemblies using noncontact atomic force microscopy. Biopoly. 42:133-146.
36. Willemsen, O. H., Snel, M.M.E., Cambi, A., Greve, J., De Grooth, B. G. & Figdor, C. G. (2000) Biomolecular interactions measured by atomic force microscopy. Biophys. J. 79:3267-3281.
37. Clark, H. A., Barker, S.L.R., Brasuel, M., Miller, M. T., Monson, E., Parus, S., Shi, Z-Y, Song, A., Thorsrud, B., Kopelman, R., Ade, A., Meixner, W., Athey, B., Hoyer, M., Hill, D., Lightle, R. & Philbert, M. A. (1998) Subcellular optohemical nanobiosensors: probes encapsulated by biologically localized embedding (PEBBLEs). Sensors and Actuators B (Chemical) 51:12-16.
38. Xu, H., Aylott, J. W., Kopelman, R., Miller, T. J. & Philbert, M. A. (2001) A real-time ratiometric method for the determination of molecular oxygen inside living cells using sol-gel based spherical optical nanosensors wwith applications to rat C6 glioma. Anal. Chem. 73:4124-4133.[Medline]
39. Clark, H. A., Hoyer, M., Philbert, M. A. & Kopelman, R. (1999) Optical nanosensors for chemical analysis inside single living cells. 1. Fabrication, characterization and methods for intracellular delivery of PEBBLE sensors. Anal. Chem. 71:4831-4836.[Medline]
40. Clark, H. A., Kopelman, R., Tjalkens, R. & Philbert, M. A. (1999) Optical nanosensors for chemical analysis insilde single living cells. Sensors for pH and calcium and the intracellular application of PEBBLE sensors. Anal. Chem. 71:4837-4843.[Medline]
41. Fenn, J. B., Mann, M., Meng, C. K., Wong, S. F. & Whitehouse, C. M. (1989) Electrospray ionization for mass spectrometry of large biomolecules. Science 246:64-71.
42. Hillenkamp, F., Karas, M., Beavis, R. C. & Chait, B. T. (1991) Matrix assisted laser desorption/ionization mass spectrometry of biopolymers. Anal. Chem. 63:1193A-1203A.[Medline]
43. VerBerkmoes, N. C., Bundy, J. L., Hauser, L., Asano, K. G., Razumovskaya, J., Larimer, R., Hettich, R. L. & Stepheson, J. L., Jr (2002) Integrating top-down and bottom-up mass spectrometric approaches for proteomic analysis of Shewanella oneidensis. J. Proteome. Res. 1:239-252.[Medline]
44. Hickenbottom, S. J., Lemke, S. L., Dueker, S. R., Lin, Y., Follett, J. R., Carkeet, C., Buchholz, B. A., Vogel, J. S. & Clifford, A. J. (2002) Dual isotope test for assessing beta-carotene cleavage to vitamin A in humans. Eur. J. Nutr. 41:141-147.[Medline]
45. Dueker, S. R., Lin, Y., Buchholz, B. A., Schneider, P. D., Lame, M. W., Segall, H. J., Vogel, J. S. & Clifford, A. J. (2000) Long-term kinetic study of beta-carotene, using accelerator mass spectrometry in an adult volunteer. J. Lipid Res. 41:1790-1800.
46. Dingley, K. H., Ubick, E. A., Chiarappa-Zucca, M. L., Nowell, S., Abel, S., Ebeler, S. E., Mitchell, A. E., Burns, S. A., Steinberg, F. M. & Clifford, A. J. (2003) Effect of dietary constituents with chemoproventive potential on adduct formation of a low dose of the heterocyclic amines PhIP and IQ and phase II hepatic enzymes. Nutr. Cancer 46:212-221.[Medline]
This article has been cited by other articles:
![]() |
F. Rohner, F. O. Ernst, M. Arnold, M. Hilbe, R. Biebinger, F. Ehrensperger, S. E. Pratsinis, W. Langhans, R. F. Hurrell, and M. B. Zimmermann Synthesis, Characterization, and Bioavailability in Rats of Ferric Phosphate Nanoparticles J. Nutr., March 1, 2007; 137(3): 614 - 619. [Abstract] [Full Text] [PDF] |
||||
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||